- Exact Sciences‘ first-quarter revenue reached $706.8 million, showing an 11% year-over-year increase, surpassing the estimated $688.7 million.
- Screening revenue totaled $540.0 million, marking a 14% increase from the previous year, and exceeded the projected $524.6 million.
- Precision Oncology revenue amounted to $166.8 million, a 2.5% increase year-over-year, slightly above the expected $164.4 million.
- The company reported a loss per share of 54 cents, an improvement from the 60-cent loss per share the previous year, but higher than the estimated 26-cent loss per share.
- Adjusted EBITDA was $63.3 million, reflecting a 61% increase year-over-year, and above the estimate of $60.8 million.
- Analyst recommendations include 25 buys, 3 holds, and 0 sells.
Exact Sciences on Smartkarma
Independent analysts on Smartkarma, like Baptista Research, are optimistic about Exact Sciences Corporation’s future. In a recent report titled “Exact Sciences Corporation: Is The Oncology Product Pipeline Development to Capture A Lion’s Share of the Market?”, Baptista Research highlighted the company’s positive momentum despite facing challenges. Exact Sciences achieved an 11% core revenue growth in 2024, totaling $2.75 billion, and significantly expanded its adjusted EBITDA by almost 48%. The company also doubled its free cash flow and closed the year with a strong $1.04 billion in cash and securities.
Furthermore, in another report titled “Exact Sciences: Expansion of the Customer Base & Provider Engagement As A Vital Tool For Growth! – Major Drivers”, Baptista Research emphasized Exact Sciences Corporation’s achievements in the third quarter of 2024. The company reported a 13% year-over-year increase in total revenue to $709 million, driven by the growth in Cologuard adoption and the international expansion of Oncotype DX. Notably, Exact Sciences saw a 75% rise in adjusted EBITDA to $99 million and achieved a record free cash flow of $113 million, illustrating significant operational efficiency improvements.
A look at Exact Sciences Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Exact Sciences Corp., a company specializing in non-invasive molecular screening for colorectal cancer, has a mixed outlook according to Smartkarma Smart Scores. With respectable scores in Value, Growth, and Momentum, the company shows promise in terms of its financial health, expansion potential, and market traction. However, Exact Sciences lags in Dividend and Resilience scores, indicating room for improvement in terms of providing returns to shareholders and withstanding economic fluctuations.
Despite facing challenges in dividend payouts and resilience, Exact Sciences Corp. remains strategically positioned in the market due to its focus on developing innovative screening tests for colorectal cancer detection. The company’s strong emphasis on value, growth, and momentum factors suggests promising long-term prospects, which could potentially drive further success and recognition in the healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
